Discover
CTOR
Citius Oncology, Inc.
0.57
1 x 0.52
1 x 0.65
bid
ask
+
0.00
0.00%
117 @ 09:02 AM
0.60 +0.03 (5.25%)
| Ytd | -43.00% | |
| 1y | -61.49% |
day range
0.49
52 week range
2.84
| Open | Prev Close | 0.57 | Low | High | Mkt Cap | 53.00M | |||
| Vol | 0.00 | Avg Vol | 75.19K | EPS | -0.47 | P/E | -1.21 | Forward P/E | N/A |
| Beta | 3.47 | Short Ratio | 0.37 | Inst. Own | 0.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.75 | 200-d Avg | 1.05 | 1yr Est | 3.00 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-27 | Maxim Group | Upgrade | Buy | |
| 2024-08-13 | EF Hutton | Upgrade | Buy | Buy |
Profile
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Yakira Capital Management, Inc. | 15.50K | 15.19K | 0.66% |
| 2024-09-29 | Virtu Financial LLC | 10.29K | 10.09K | 0.44% |
| 2024-09-29 | Osaic Holdings Inc | 5.48K | 5.37K | 0.23% |
| 2024-09-29 | UBS Group AG | 1.63K | 1.60K | 0.07% |
| 2024-09-29 | Bank of America Corporation | 160.00 | 156.00 | 0.01% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 41.00 | 40.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 2.33K | 2.29K | 0.10% |